Ortho-Novum 7/7/7

1. See Also
   1. Oral Contraceptive
   2. Oral Contraceptive Drug Interaction
   3. Oral Contraceptive Selection
   4. Oral Contraceptive Side Effect Management
   5. Oral Contraceptive-Related Uterine Bleeding Management
2. Preparations (Norethindrone / Ethinyl Estradiol)
   1. Ortho-Novum 10/11 Biphasic (0.5 - 1.0 / 35)
   2. Ortho-Novum 7/7/7 Triphasic (0.5 - 0.75 - 1.0 / 35)
   3. Tri-Norinyl Triphasic (0.5 - 1.0 - 0.5 / 35)
3. Components
   1. Norethindrone 0.5 to 1.0 (see preparations above)
   2. Ethinyl Estradiol 35 ug
4. Effect
   1. Relative Progestational Activity: 0.8 (moderate)
   2. Estrogenic Activity: 48 (high)
   3. Androgenic Activity: 0.25 (moderate)
5. Pill associated problems
   1. Indications to switch to Ortho Cyclen
      1. Acne Vulgaris (lower androgen)
      2. Increased Appetite (lower Progestin)
      3. Major Depression provoked (lower Progestin)
   2. Indications to switch to Demulen 1/35
      1. Breast Tenderness or engorgement (lower Estrogen)
      2. Break-through bleed days 10-21 (more Progestin)
      3. Headaches (lower Estrogen)
      4. Heavy Menses (more Progestin or less Estrogen)
      5. Dysmenorrhea or Menstrual Cramps (more Progestin)
      6. Moodiness (less Estrogen or more Progestin)
      7. Weight gain (less Estrogen or more Progestin)
   3. Indications to switch to Modicon
      1. Break-through bleed days 1-9 (more Estrogen)
      2. Break-through bleed all of month (more Estrogen)
      3. Menses too light (more Estrogen, less Progestin)
   4. Indications to switch to Nordette
      1. Libido decreased (more androgen)
6. References
   1. Cerel-Suhl (1999) Am Fam Physician 60(7):2073
   2. Speroff (1993) Obstet Gynecol 81:1034-47
   3. Dickey (1998) Managing Contraceptive Pill Patients